Comparative Pharmacology
Head-to-head clinical analysis: CORTAN versus LOCOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTAN versus LOCOID.
CORTAN vs LOCOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
Topical: Apply a thin layer to affected area once or twice daily. Maximum: 30-60 g per week. Not for use >2 consecutive weeks or on >50% of body surface.
None Documented
None Documented
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Terminal elimination half-life: 30-40 hours; clinically significant for once-daily dosing and prolonged action
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Renal (approximately 60-70%) as conjugated metabolites; biliary/fecal (approximately 20-30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid